CMPCPS-001 is under clinical development by CAMP4 Therapeutics and currently in Phase I for Urea Cycle Disorders. According to GlobalData, Phase I drugs for Urea Cycle Disorders have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CMPCPS-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CMPCPS-001 overview

CMP-CPS-001 is under development for the treatment of urea cycle disorder. The drug candidate is administered through subcutaneous route. It acts by targeting carbamoyl phosphate synthetase 1 (CPS1) enzyme. It is being developed based on RNA actuating platform (RAP).

CAMP4 Therapeutics overview

CAMP4 Therapeutics is a bio-technology company that develops therapies for the treatment of various diseases. The Company is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of CMPCPS-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.